CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers
- 23 November 2005
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 55 (9) , 1064-1071
- https://doi.org/10.1007/s00262-005-0092-8
Abstract
Purpose: Regulatory T cells (T regs) can inhibit immune responses mediated by T cells. It has been shown that there is an increased proportion of T regs in several different human malignancies, although the actual mechanism remains unclear. In the present study, we evaluated the prevalence of CD4(+)CD25high T regs in PBMCs from patients with gastric and esophageal cancers in relation to the clinical outcome. Methods: PBMCs in 72 patients with gastric cancer and 42 patients with esophageal cancer were evaluated for the proportion of CD4(+)CD25high T cells, as a percentage of the total CD4(+) cells, by flow cytometric analysis with triple-color staining. Actuarial overall survival rates of the patients were analyzed by the Kaplan–Meier method. Results: The percentages of CD4(+)CD25high T cells for cases of gastric cancer (4.9±1.2%) and esophageal cancer (5.2±2.1%) were significantly higher than those for healthy donors (1.9±1.1%, Phigh T cells between the early and advanced disease stages, both in gastric cancer (stage I vs. III, PPPhigh T cells showed poorer survival rates in comparison to those with a low proportion, in both gastric and esophageal cancers. After patients received curative resections of gastric cancers (n=57), the increased proportions of CD4(+)CD25high T cells were significantly reduced, and the levels were almost equal to those in normal healthy donors. In addition, studies of gastric cancer patients with postoperative recurrent tumors (n=6) revealed that the prevalence of CD4(+)CD25high T cells individually increased compared to 2 months after the operations. CD4(+)CD25high T cells expressed FOXP3 mRNA and had abundant CD45RO and intracellular CTLA-4 molecules. Conclusions: These results strongly suggest that tumor-related factors induce and expand CD4(+)CD25high T regs.Keywords
This publication has 24 references indexed in Scilit:
- Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4CD25 T cellsClinical Immunology, 2005
- Distribution of CD4(+)CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancerJournal of Surgical Research, 2005
- Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNature Medicine, 2004
- Human CD4+CD25+ regulatory T cellsSeminars in Immunology, 2004
- CD4+CD25+ regulatory T cells in patients with gastrointestinal malignanciesCancer, 2003
- Human CD25+CD4+ T Suppressor Cell Clones Produce Transforming Growth Factor β, but not Interleukin 10, and Are Distinct from Type 1 T Regulatory CellsThe Journal of Experimental Medicine, 2002
- Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte ResponsesThe Journal of Experimental Medicine, 2001
- Certified ProfessionalsThe Journal of Experimental Medicine, 2001
- Regulatory T CellsCell, 2000
- Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation.The Journal of Experimental Medicine, 1996